Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy?

Keyphrases

• Ischemic Heart Disease 100%
• Vascular Endothelial Growth Factor 100%
• Disease Genes 100%
• Recombinant 100%
• Protein Therapy 100%
• Therapeutic Angiogenesis 100%
• Vascular Growth Factors 100%
• Protein-coding Genes 50%
• OR Genes 50%
• Large-scaled 50%
• VEGF165 50%
• Gene Encoding 50%
• Fibroblast Growth Factor 2 (FGF2) 50%
• Cardiovascular Disease 25%
• Clinical Effect 25%
• Randomized Placebo-controlled Trial 25%
• Clinical Trials 25%
• Potential Treatments 25%
• Slow Release 25%
• Revascularization 25%
• Coronary Artery Bypass Grafting 25%
• Balloon Angioplasty 25%
• Patients with Coronary Artery Disease 25%
• Gene Therapy 25%
• Recombinant Protein 25%
• Basic Fibroblast Growth Factor (bFGF) 25%
• Phase I Study 25%
• Vascular Growth 25%
• Efficacy Trial 25%
• Safety Trial 25%
• Fibroblast Growth Factor 1 (FGF1) 25%
• Ischemic Myocardium 25%
• Intracoronary Infusion 25%
• Growth Factor Therapy 25%
• Protein Formulation 25%
• Atherosclerotic Coronary Artery Disease 25%
• Severe Coronary Artery Disease 25%
• Clinical Phase 25%
• Treatment Regime 25%

Medicine and Dentistry

• Growth Factor 100%
• Ischemic Heart Disease 100%
• Vasculotropin 100%
• Angiogenesis 100%
• Protein Therapy 100%
• Coronary Artery Disease 75%
• Fibroblast Growth Factor 2 75%
• Recombinant Vasculotropin 50%
• Placebo-Controlled Study 25%
• Cardiovascular Disease 25%
• Clinical Trial 25%
• Revascularization 25%
• Percutaneous Transluminal Angioplasty 25%
• Coronary Artery 25%
• Intracoronary Drug Administration 25%
• Heart Muscle Ischemia 25%
• Gene Therapy 25%
• Grafting 25%
• Recombinant Protein 25%
• Vasculotropin A 25%
• Fibroblast Growth Factor 1 25%
• Protein Secretion 25%
• 1 [2 (1,1 Dimethylallyl) 2,3 Dimethyl 3 Furyl] 3,5 Dihydroxy 4 Methoxy 2 Hexanone 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Ischemic Heart Disease 100%
• Growth Factor 100%
• Vasculotropin 100%
• Coronary Artery Disease 75%
• Fibroblast Growth Factor 2 75%
• Recombinant Vasculotropin 50%
• Placebo-Controlled Study 25%
• Clinical Trial 25%
• Heart Muscle Ischemia 25%
• Vasculotropin A 25%
• Recombinant Protein 25%
• Fibroblast Growth Factor 1 25%
• 1 [2 (1,1 Dimethylallyl) 2,3 Dimethyl 3 Furyl] 3,5 Dihydroxy 4 Methoxy 2 Hexanone 25%
• Protein Formulation 25%
• Cardiovascular Disease 25%